Features of 168 young Japanese women grouped by tertile of serum orosomucoid concentrations
Tertile | First | Second | Third | |
Range (mg/dL) | <112 | 113–134 | ≥135 | |
Orosomucoid (mg/dL) | 100±10 | 125±6 | 155±20 | abc |
Age (years) | 20.3±1.1 | 20.3±1.0 | 20.6±1.1 | |
Fat mass index (kg/m2) | 5.6±1.6 | 5.3±1.8 | 5.2±1.8 | |
Waist circumference (cm) | 73.3±5.5 | 73.5±5.5 | 72.9±5.9 | |
Percentage body fat (%) | 26.6±6.1 | 25.5±6.1 | 25.2±6.3 | |
Trunk/leg fat ratio | 1.24±0.24 | 1.24±0.25 | 1.21±0.24 | |
Leptin (ng/mL) | 7.7±3.5 | 7.3±3.5 | 7.6±4.2 | |
Adiponectin (µg/mL) | 13.4±5.1 | 12.2±4.5 | 11.6±4.1 | |
hsCRP (μg/dL) | 44±97 | 23±33 | 32±48 | |
PAI-1 (ng/mL) | 24±9 | 29±14 | 26±13 | |
Fasting glucose (mg/dL) | 82±6 | 84±6 | 86±7 | b |
30 min glucose (mg/dL) | 97±13 | 123±8 | 148±20 | abc |
1 hour glucose (mg/dL) | 79±17 | 100±18 | 129±35 | abc |
2 hours glucose (mg/dL) | 80±12 | 91±17 | 104±24 | abc |
Fasting insulin (μU/mL) | 5.8±3.5 | 5.7±2.3 | 5.9±3.4 | |
30 min insulin (μU/mL) | 56±35 | 53±25 | 52±33 | |
1 hour insulin (μU/mL) | 32±17 | 43±20 | 52±31 | ab |
2 hours insulin (μU/mL) | 32±25 | 35±20 | 42±25 | |
Δglucoe30 (mg/dL) | 15±14 | 40±8 | 62±18 | abc |
Δinsulin30 (µU/mL) | 50±35 | 47±24 | 46±32 | |
AUCg (mg/dL, 2 hours) | 168±18 | 203±19 | 245±38 | abc |
AUCi (µU/mL, 2 hours) | 70±32 | 78±29 | 87±43 | b |
HOMA-IR | 1.17±0.69 | 1.19±0.51 | 1.27±0.80 | |
Matsuda index | 10.8±4.2 | 9.1±3.6 | 8.8±4.7 | b |
IGI | 10.2±20.9 | 1.2±0.6 | 1.2±3.4 | ab |
Athletes (n, %) | 17 30.4 | 18, 32.1 | 15, 26.8 |
Mean±SD (n=56) in each tertile. Significantly different at p<0.05 or less.
a and b: first vs second and third tertile, respectively, c: second vs third tertile.
AUCg, area under the concentration curve of glucose; AUCi, area under the concentration curve of insulin; FMI, fat mass index; Δglucose30 and Δinsulin30, incremental 30 min glucose and insulin concentrations, respectively; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP, high-sensitivity C reactive protein; IGI, insulinogenic index; PAI-1, plasminogen activator inhibitor-1.